Noscapine-13C,d3
CAT:
804-HY-13716S
Size:
1 mg
Price:
Ask
- Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
- Dry Ice Shipment: No

Noscapine-13C,d3
- CAS Number: 1217680-57-3
- UNSPSC Description: Noscapine-13C,d3 is a deuterated labeled Noscapine[1]. Noscapine ((S,R)-Noscapine) is an orally active phthalideisoquinoline alkaloid with potent antitussive. Noscapine exerts its antitussive effects by activating sigma opioid receptors and is a non-competitive Bradykinin inhibitor. Noscapine disrupts microtubule dynamics, induces mitotic arrest and apoptosis. Noscapine possesses anticancer, neuroprotective, anti-inflammatory activities, and can cross the blood-brain barrier[2][3][4][5][6].
- Target Antigen: Apoptosis; Isotope-Labeled Compounds; Opioid Receptor
- Type: Isotope-Labeled Compounds
- Related Pathways: Apoptosis;GPCR/G Protein;Neuronal Signaling;Others
- Applications: Cancer-programmed cell death
- Field of Research: Cancer
- Smiles: COC1=C(OCO2)C2=CC3=C1[C@@]([C@]4([H])C5=CC=C(OC)C(OC)=C5C(O4)=O)([H])N(CC3)[13C]([2H])([2H])[2H]
- Molecular Weight: 417.43
- References & Citations: [1] Jaren W Landen, et al. Noscapine Crosses the Blood-Brain Barrier and Inhibits Glioblastoma Growth. Clin Cancer Res. 2004 Aug 1;10(15):5187-201.|[2]Yunfan Yang, et al. CYLD Regulates Noscapine Activity in Acute Lymphoblastic Leukemia via a Microtubule-Dependent Mechanism. Theranostics. 2015 Mar 2;5(7):656-66.|[3]Vartika Tomar, et al. Noscapine and Its Analogs as Chemotherapeutic Agent: Current Updates. Curr Top Med Chem. 2017;17(2):174-188.|[4]Bianca Lokhorst, et al. Interaction of OTC Drug Noscapine and Acenocoumarol and Phenprocoumon. Br J Clin Pharmacol. 2019 May;85(5):1041-1043.|[5]S A Ebrahimi, et al. Interaction of Noscapine With the Bradykinin Mediation of the Cough Response. Acta Physiol Hung. 2003;90(2):147-55.|[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
- Shipping Conditions: Room temperature
- Clinical Information: No Development Reported